YOLFTbeta
68

Zhejiang Orient Gene Biotech Co Ltd

688298 · SHG · Healthcare / Medical Devices

17.64CNY-1.16 (-6.17%)

Price History

Full chart

Market Stats

Previous Close18.80
Open18.33
Day Range17.60 – 18.47
52-Week Range17.03 – 28.99
Volume4.25M
Market Cap3.90B
P/E (TTM)0.00
Forward P/E0.00
EPS-3.30
Dividend Yield0.00%
Beta0.83
50-Day Avg18.96
200-Day Avg21.72

About

Zhejiang Orient Gene Biotech Co., Ltd researches and develops, produces, and sells in vitro diagnostic products in China and internationally. Its products include POCT instant diagnostic reagents that are used for detection of infectious diseases, drugs of abuse, fertility, tumor marker, and cardiac marker detection. The company also offers human and animal health products; and raw materials for rapid testing, fluorescent immunoassay, western blot, biochemistry, and molecular diagnostics. It serves pharmacies chain, supermarkets, tertiary hospitals, healthcare institutions, third-party laboratories, medical distributors, and pharmaceutical distribution clients. Zhejiang Orient Gene Biotech Co., Ltd was incorporated in 2005 and is based in Huzhou, China.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Xiaoliang Fang
  • Employees2.07K
  • HeadquartersNo. 3787, East Yangguang Avenue, Huzhou, China, 313300, China
  • Websitehttps://www.orientgene.com

Leadership

  • Mr. Xiaoliang FangGM & Director · b. 1957
  • Mr. Shichang XiFinancial Officer · b. 1974
  • Ms. Ye Ping ZhangDeputy GM & Secretary · b. 1979
  • Ms. Pang QiDeputy General Manager · b. 1967
  • Mr. Jinhong YuDeputy General Manager · b. 1971
  • Ms. Jinfeng TanDeputy General Manager · b. 1982
  • Ms. Chunmei ZhongDeputy General Manager · b. 1979
  • Ms. Faying XuDeputy General Manager · b. 1975
  • Mr. Yun Ou YangDeputy General Manager · b. 1976
  • Yuanyuan LiAccounting Supervisor

Financials

Income Statement

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue182.26M224.24M285.89M367.38M3.27B10.17B8.77B820.16M827.92M958.99M
Growth (%)-+23.03%+27.50%+28.50%+788.83%+211.43%-13.78%-90.65%+0.95%+15.83%
Cost of Revenue95.54M118.11M149.01M194.87M753.24M2.68B5.16B640.51M659.26M560.90M
Gross Profit86.72M106.13M136.88M172.51M2.51B7.49B3.61B179.64M168.66M958.99M
Gross Margin47.58%47.33%47.88%46.96%76.93%73.63%41.18%21.90%20.37%100.00%
Operating Expense46.40M68.91M61.73M81.48M537.77M1.71B1.08B563.48M747.49M1.53B
Operating Income40.32M37.22M75.16M91.03M1.97B5.78B2.53B-383.83M-578.83M-575.82M
Operating Margin22.12%16.60%26.29%24.78%60.46%56.80%28.83%-46.80%-69.91%-60.04%
EBITDA54.97M47.84M86.97M100.54M1.98B5.80B2.56B-234.78M-385.53M-397.87M
EBITDA Margin30.16%21.34%30.42%27.37%60.69%57.03%29.15%-28.63%-46.57%-41.49%
Net Income35.63M32.71M65.37M82.11M1.68B4.92B2.07B-397.58M-529.02M-563.62M
Net Income Margin19.55%14.59%22.87%22.35%51.37%48.38%23.58%-48.48%-63.90%-58.77%
R&D9.26M12.30M18.64M31.76M93.75M428.52M511.56M260.86M290.49M230.81M
R&D as % of Total Revenue5.08%5.49%6.52%8.64%2.87%4.21%5.83%31.81%35.09%24.07%
Interest Expense7.76M3.43M4.49M2.86M1.19M2.39M8.78M19.26M20.58M9.91M
Interest Expense % of Total Revenue4.26%1.53%1.57%0.78%0.04%0.02%0.10%2.35%2.49%1.03%

Balance Sheet

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets241.00M259.32M337.65M361.51M3.57B8.98B10.70B9.00B8.09B7.14B
Total Liabilities142.28M121.20M129.62M107.38M1.12B2.09B2.38B1.45B1.30B1.05B
Total Equity98.72M133.49M201.03M251.73M2.45B6.86B8.16B7.44B6.65B5.99B
Cash80.79M77.91M102.55M85.44M2.04B6.10B6.60B4.16B3.08B2.45B
Total Debt76.00M56.00M50.00M27.00M5.22M18.49M82.20M608.33M163.95M-
Net Debt-4.79M-21.91M-52.55M-58.43M-2.03B-6.08B-6.51B-3.56B-2.92B-

Cash Flow

Currency: CNY2016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow11.81M33.54M44.33M54.21M1.79B5.20B3.00B-1.60B-348.33M-193.90M
Investing Cash Flow85.45M-15.76M-18.75M-11.73M-548.84M-321.64M-2.38B-2.16B-670.15M-
Financing Cash Flow-28.36M-18.22M-5.72M-60.29M503.29M-509.17M-698.25M49.54M-451.74M-
Capital Expenditure4.65M13.38M18.88M11.90M126.93M507.87M1.05B996.05M924.09M307.67M
Free Cash Flow7.16M20.16M25.45M42.31M1.66B4.70B1.94B-2.64B-1.27B-501.57M
Dividends Paid6.71M3.92M3.68M33.22M25.29M504.67M742.04M351.14M16.63M6.71M
FCF to OCF60.60%60.10%57.41%78.05%92.91%90.24%64.89%164.89%365.30%258.67%
Dividend Paid to FCF93.77%19.43%14.45%78.51%1.52%10.75%38.17%-13.29%-1.31%-1.34%

Earnings

Report DateMar 31, 2020Jun 30, 2020Sep 30, 2020Feb 26, 2021Apr 28, 2021Aug 29, 2021Oct 29, 2021Feb 25, 2022Apr 27, 2022Aug 29, 2022Oct 30, 2022Dec 31, 2022Apr 27, 2023
EPS Estimate-------------
EPS Actual0.222.380.706.039.8913.143.135.9612.304.021.84-4.88-5.86
Surprise-------------
Timing---After-hoursAfter-hoursPre-marketAfter-hoursAfter-hoursPre-marketPre-marketAfter-hours-Pre-market

Key Statistics & Ratios

Market Cap3.90B
Enterprise Value1.96B
Trailing P/E0.00
Forward P/E0.00
Price / Sales3.87
Price / Book0.68
EPS-3.30
Book Value30.07
Revenue (TTM)1.01B
Gross Profit (TTM)411.95M
EBITDA-248.20M
Profit Margin-62.74%
Operating Margin-52.51%
Return on Equity-10.54%
Return on Assets-3.63%
Shares Outstanding201.60M
Shares Float93.50M
Beta0.83
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Dividends

20231×
2.00Jun 26, 2023
20221×
5.15Jun 16, 2022
20211×
2.50Jul 9, 2021
20201×
0.13Jun 10, 2020

Stock Splits

  • Jun 26, 20236:5
  • Jun 16, 20227:5